- Trials with a EudraCT protocol (39,286)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
39,286 result(s) found for: $1.
Displaying page 235 of 1,965.
EudraCT Number: 2004-000959-42 | Sponsor Protocol Number: P03708 | Start Date*: 2004-09-06 |
Sponsor Name:Integrated Therapeutics Group, Inc./Schering-Plough Oy | ||
Full Title: Avoin, randomis., rinnakkaisryhmillä tehtävä monikeskustutk., jossa tutk. tehoa ja turvallisuutta vertailtaessa lääkityksen vaihtamista rosuvastatiiniin 10 mg päivässä verrattuna atorvastatiiniin... | ||
Medical condition: Korkean riskin, erityisesti sepelvaltimotautia ja diabetesta sairastavat potilaat, joilla dieeti- ja liikuntaohjeista huolimatta Ldl-kolesteroli on yli suositusarvon 2.5 mmol/l. Suositusten mukaine... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: FI (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-001891-35 | Sponsor Protocol Number: D4200C00080 | Start Date*: 2007-06-22 | |||||||||||
Sponsor Name:AstraZeneca SAS | |||||||||||||
Full Title: A randomized, double-blind phase II trial to assess the efficacy and safety of bicalutamide (Casodex® ) associated to ZD6474 (Zactima™ ) or to placebo in patients with castration-refractory metasta... | |||||||||||||
Medical condition: Metastatic prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001034-10 | Sponsor Protocol Number: SativexStroke | Start Date*: 2016-12-07 | |||||||||||
Sponsor Name:IRCCS-A.O.U. SAN MARTINO-IST | |||||||||||||
Full Title: Neurophysiological assessment of the effect of Sativex (THC/CBD oromucosal spray) as add-on to treat spasticity following stroke | |||||||||||||
Medical condition: Spasticity following stroke | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-005140-24 | Sponsor Protocol Number: ISIS 301012-CS19 | Start Date*: 2008-06-05 | |||||||||||
Sponsor Name:Isis Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled STudy to Assess Safety and Efficacy of ISIS 301012 Administration in Statin Intolerant Subjects | |||||||||||||
Medical condition: Patients with hypercholesterolemia who are intolerant to statins | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-001249-14 | Sponsor Protocol Number: 102547 | Start Date*: 2004-10-18 |
Sponsor Name:GlaxoSmithKline | ||
Full Title: A Phase III open, multicentre, booster vaccination study to assess the immunogenicity, safety and reactogenicity of a booster dose of GlaxoSmithKline (GSK) Biologicals’ Haemophilus influenzae type ... | ||
Medical condition: Booster vaccination against Haemophilus influenzae type b and meningococcal serogroup C diseases. | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-000665-35 | Sponsor Protocol Number: PM0259CA220B0 | Start Date*: 2004-09-08 |
Sponsor Name:Pierre Fabre Medicament | ||
Full Title: Phase II study of oral vinorelbine in combination with capecitabine in metastatic breast cancer patients previously treated with anthracyclines and taxanes | ||
Medical condition: Treatment in metastatic breast cancer women previously treated with anthracyclines and taxanes | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-005935-14 | Sponsor Protocol Number: 3200K1-3358-WW | Start Date*: 2009-04-24 | |||||||||||
Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc. | |||||||||||||
Full Title: An Open-Label Study to Evaluate the Long-term Safety of Subcutaneous MOA-728 for Treatment of Opioid-Induced Constipation in Subjects With Nonmalignant Pain Estudio abierto para evaluar la segurida... | |||||||||||||
Medical condition: Opioid-induced constipation in subjects with non-malignant pain Tratamiento del estreñimiento inducido por opiáceos en sujetos con dolor de origen no maligno | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-002812-10 | Sponsor Protocol Number: PADD-ON | Start Date*: 2012-01-03 | |||||||||||
Sponsor Name:University Medical Center of the Johannes Gutenberg University Mainz | |||||||||||||
Full Title: A prospective, randomised, open-label phase IIb clinical trial assessing the effect of pegylated Interferon alfa-2a (Pegasys®) 180 µg once weekly for 48 weeks in addition to an ongoing nucelos(t)id... | |||||||||||||
Medical condition: Patients with chronic HBeAg-negative hepatitis B with a stable oral antiviral treatment (not containing telbivudine) and a fully suppressed viral load for at least 12 months (below limit of detecti... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-006127-34 | Sponsor Protocol Number: 1.3 | Start Date*: 2021-09-17 |
Sponsor Name:Verein zur Förderung der Wissenschaft und Forschung an der 1.Med. Abteilung der Krankenanstalt Rudolfstiftung | ||
Full Title: Empagliflozin as potential treatment option for postprandial hyperinsulinemic hypoglycaemia after bariatric surgery – a pilot study | ||
Medical condition: Postprandial hyperinsulinemic hypoglycaemia (PHH) typically occurs years after bariatric surgery and one to three hours after a carbohydrate-rich meal. It is caused by rapid gastric emptying of und... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2015-003111-38 | Sponsor Protocol Number: 6630-9050-03 | Start Date*: 2015-12-30 |
Sponsor Name:Medice Arzneimittel Pütter GmbH & Co. KG | ||
Full Title: A double-blind, randomized, placebo-controlled, parallel-group study comparing safety and efficacy of Dorithricin® lozenges with placebo in the symptomatic treatment of patients with acute pharyngitis | ||
Medical condition: Acute pharyngitis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-004019-34 | Sponsor Protocol Number: ABI-H0731-211 | Start Date*: 2019-02-20 |
Sponsor Name:Assembly Biosciences | ||
Full Title: A Multi-center, Open-label, Long-term Extension Study of ABI-H0731 + Nucleos(t)ide as Finite Treatment for Chronic Hepatitis B Patients | ||
Medical condition: Chronic Hepatitis B | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: View results |
EudraCT Number: 2008-002467-13 | Sponsor Protocol Number: RRG8.46-RRG/3273/05-1 | Start Date*: 2009-05-06 | |||||||||||
Sponsor Name:Northern Health and Social Care Trust | |||||||||||||
Full Title: A non-inferiority study of the clinical effectiveness of anaesthesia obtained via application of Topical Anaesthetic Gel compared to infiltration of lidocaine for the treatment of lacerations in th... | |||||||||||||
Medical condition: Small to medium sized lacerations with no underlying nerve or other gross structural damage which would require further medical or surgical investigation. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001707-31 | Sponsor Protocol Number: Protocolversion1.0 | Start Date*: 2015-07-10 |
Sponsor Name:Hull & East Yorkshire Hospitals NHS Trust | ||
Full Title: The SCaIPEL study: Survival and Quality of Life of Cancer Patients with Incidental Pulmonary Embolism Treated with LMWH | ||
Medical condition: Incidental Pulmonary Embolism in Cancer Patients | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2012-000709-59 | Sponsor Protocol Number: LCCC1029 | Start Date*: 2012-06-07 | |||||||||||
Sponsor Name:The Irish Clinical Oncology Research Group | |||||||||||||
Full Title: A Multi-Center, Randomized, Placebo-Controlled Phase II Study of Regorafenib in Combination With FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) Versus Placebo With FOLFIRI as Second-Line Ther... | |||||||||||||
Medical condition: Second-Line Therapy in Patients with Metastatic Colorectal Cancer. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-006743-31 | Sponsor Protocol Number: DV2-HBV-10 | Start Date*: 2007-06-12 | |||||||||||
Sponsor Name:Dynavax Technologies Corporation | |||||||||||||
Full Title: A Phase III Safety and Efficacy Study to Compare Immune Responses following Injection with Either Two Doses of HEPLISAV™ or Three Doses of Engerix-B® | |||||||||||||
Medical condition: Prevention of Hepatitis B Virus (HBV) infection. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001324-33 | Sponsor Protocol Number: APHP200392 | Start Date*: 2020-04-09 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS (APHP) | |||||||||||||
Full Title: Use of a respiratory multiplex PCR and procalcitonin to reduce antibiotic exposure in patients with severe confirmed COVID-19 pneumonia : a multicenter, parallel-group, open-label, randomized contr... | |||||||||||||
Medical condition: Severe confirmed COVID-19 pneumonia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-001179-39 | Sponsor Protocol Number: 2005108 | Start Date*: 2006-10-11 | |||||||||||
Sponsor Name:Procter & Gamble Pharmaceuticals | |||||||||||||
Full Title: A Randomised, Double-Blind, Placebo-Controlled, Parallel-group, Multicentre, 24 week Study to Evaluate the Efficacy and Safety of Transdermal Testosterone (300 mcg/day) in Naturally Menopausal Wome... | |||||||||||||
Medical condition: Hypoactive sexual desire disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-016682-28 | Sponsor Protocol Number: ARhiSi-2 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Bionorica AG | |||||||||||||
Full Title: A multi-centre, double-blind, placebo-controlled, randomised, parallel group study to assess the efficacy and safety of a herbal medicinal product (dry extract BNO-1016) in patients with acute rhi... | |||||||||||||
Medical condition: Acute rhinosinusitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-003981-42 | Sponsor Protocol Number: 2012.2708 | Start Date*: 2014-10-20 |
Sponsor Name:University Medical Center Groningen [...] | ||
Full Title: Estrogen receptor and androgen receptor imaging in metastatic breast cancer patients | ||
Medical condition: Estrogen receptor positive metastatic breast cancer patients | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-004736-79 | Sponsor Protocol Number: 1102-CT02 | Start Date*: 2007-03-06 |
Sponsor Name:Antisense Therapeutics Ltd. | ||
Full Title: A double-blind, placebo-controlled, randomised trial to prove the therapeutic concept and to determine the pharmacokinetic profile of ATL 1102 (VLA-4 antisense oligonucleotide) by subcutaneous inje... | ||
Medical condition: To evaluate the efficacy of a selected treatment regimen of ATL 1102 in patients with Relapsing Remitting MS (RRMS) inflammatory lesions using MRI with gadolinium administration compared to placebo. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: CZ (Completed) SK (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
